Boehringer Ingelheim
As of the edition of 20 October 2026, Boehringer Ingelheim runs 204 drugs, 42 of them marketed; it is on route A at 30 targets and on route B at 20 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Boehringer Ingelheim was renamed in 2008.
The records place 2 company names in this family.
- BOEHRINGER INGELHEIM: renamed in 2008
Drugs by status
| Status | Count |
|---|---|
| Marketed | 42 |
| Active | 36 |
| Went quiet | 52 |
| Stopped | 56 |
| Status not established | 18 |
| Total | 204 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Empagliflozin | Ends 2028 (patent) | 1 |
| Amlodipine | none listed | 16 |
| Duloxetine | none listed | 2 |
| Albuterol | none listed | 2 |
| Tiotropium | none listed | 0 |
| Hydrochlorothiazide | none listed | 4 |
| Telmisartan | none listed | 2 |
| Afatinib | Ends 2029 (patent) | 1 |
| Nintedanib | Ends 2027 (exclusivity) | 9 |
| Clonidine | none listed | 0 |
| Tamsulosin | none listed | 3 |
| Linagliptin | Ends 2026 (exclusivity) | 1 |
| Nevirapine | none listed | 0 |
| Dabigatran etexilate | Ended 2025 (patent) | 1 |
| Alteplase | Ended 1999 (computed from the first US licence) | 0 |
| Dabigatran | none listed | 1 |
| Tenecteplase | Ended 2012 (computed from the first US licence) | 0 |
| Pramipexole | none listed | 5 |
| Meloxicam | none listed | 1 |
| Risankizumab | Ends 2031 (computed from the first US licence) | 1 |
| Olodaterol | Ends 2027 (patent) | 0 |
| Ipratropium | none listed | 0 |
| Tipranavir | none listed | 0 |
| Alovudine | none listed | 0 |
A route B row is one company at one target. 17 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 30 targets, route B at 20 targets.
All 50 rows on route A or B
In the product50 company-target rows on route A or B; 47 are not shown here, and no score is.
See all 50 targets where Boehringer Ingelheim needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Lungs and airways: 285 trials led
- Cancer: 209 trials led
- Heart and blood vessels: 133 trials led